Lv4
480 积分 2024-10-07 加入
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
2天前
求助中
Association of Thrombocytopenia with Disease Burden, High-Risk Features, and Survival in Multiple Myeloma
3天前
已完结
Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials
1个月前
已完结
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
1个月前
已完结
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
1个月前
已完结
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
5个月前
已完结
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma
6个月前
已完结
Real World Analysis of the efficacy, prognosis, and safety of daratumumab, carfilzomib, and dexamethasone (DKd) in relapsed or refractory multiple myeloma patients
7个月前
已完结
Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients
7个月前
已关闭
皖公网安备34019202002308
